Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Feb 14, 2021 1:54pm
165 Views
Post# 32565077

RE:Our platform is an iceberg and we are only seeing the tip !

RE:Our platform is an iceberg and we are only seeing the tip !
Goaweigh wrote: I'm fascinated by the potential of this drug platform and how it might impact people with IBD. 
Remember reading a paper co authored by Dr. Wallace in collaboration with another Dr. in Edmonton or Calgary, can't remember now, but they had done some work with H2S on IBD with significant results I believe. 
I read somewhere that IBD effects 3,000,000 people in NA so that is a huge market. It doesn't compare to the sheer numbers of people who take NSAIDS every day but the dollars per pill for an NSAID will be pretty low while the dollars of revenue for a disease like IBD would be huge.
We could have a cure and that is significant, if only $ 1000 per person per year, which isn't that much given the benefits, that's a $ 3 Billion drug. Could be much higher.
Don't know the multiple on sales/revenue on a blockbuster drug like that but I believe that's where our real value lies....hidden beneath the surface and the success of ATB-346 will help reveal what's really here ! 




We had 2 drugs for IBD ... ATB-428 and ATB-429.
They really don't talk to these drugs anymore.

https://antibethera.com/news/calgary-researchers-discover-a-novel-approach-to-treatment-of-inflammatory-bowel-diseases-ibd-using-hydrogen-sulfide-technology/

Not sure what the priority of the new IBD drug is or if it only gets advanced if it is acquired or partnered in some collaboration.

Curious what they're thinking at ATE.
<< Previous
Bullboard Posts
Next >>